Stocktoria
JUPITER NEUROSCIENCES, INC. JUNS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-12-03
JUPITER NEUROSCIENCES, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $21,796 | $0 | — |
| Gross profit | $17,565 | — | — |
| R&D expense | $2.1M | $492,660 | $954,793 |
| SG&A expense | $6.8M | — | — |
| Operating income | -$8.9M | -$3.1M | -$3.9M |
| Net income | -$8.6M | -$2.4M | -$4.8M |
| EPS (diluted) | $-0.25 | $-0.08 | $-0.18 |
| Operating cash flow | -$5.4M | -$3.9M | -$480,953 |
| Inventory | $159,790 | — | — |
| Total assets | $5.6M | $6.2M | $148,592 |
| Total liabilities | $7.4M | $2.0M | $5.9M |
| Shareholders' equity | -$1.8M | $4.2M | -$5.8M |
Source: SEC EDGAR filings · CIK 0001679628 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.